{"id":31259,"date":"2014-09-16T11:44:37","date_gmt":"2014-09-16T15:44:37","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=31259"},"modified":"2014-09-16T11:44:37","modified_gmt":"2014-09-16T15:44:37","slug":"gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259","title":{"rendered":"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 In order to sell hepatitis C pill- <a href=\"http:\/\/online.wsj.com\/articles\/gilead-to-allow-cheaper-hepatitis-c-drug-1410779963?ru=yahoo?mod=yahoo_itp\" target=\"_blank\"><strong>Sovaldi<\/strong><\/a>, in developing countries like South Africa, Vietnam and Honduras, <strong>Gilead Sciences, Inc. (NASDAQ:GILD)<\/strong> authorized various drug companies in India. The actual price of hepatitis C pill of the company is $1,000-a-day, which will now be sold at just a dime in the aforesaid countries.<\/p>\n<p style=\"text-align: justify;\"><strong>Licensing Deals Signed<\/strong><\/p>\n<p style=\"text-align: justify;\">The biotech company based in California said that various licensing deals and agreements have been signed with generic pharma companies of India, which include <strong>Mylan Inc (NASDAQ:MYL)<\/strong>, <strong>Ranbaxy Laboratories Limited (ADR) (OTCMKTS:RBXLY)<\/strong> and <strong>Cipla Ltd (ADR) (OTCMKTS:CPLFY)<\/strong>. Sovaldi shall now be sold in 91 countries. The countries chosen to be included in licensing deal include over half of the hepatitis C population of the world.<\/p>\n<p style=\"text-align: justify;\"><strong>Lower Price in Developing Nations<\/strong><\/p>\n<p style=\"text-align: justify;\">Gilead Sciences announced that the price of a Sovaldi bottle in India would be $300. A few other generic companies in India, in the meanwhile, said that the price of this medicine would be even lesser for their versions. This indicates that the patients of hepatitis C in 91 developing countries of the world will pay $10 per day for this medicine. Interestingly, it is just 1% price of what is being charged by the U.S. patients.<\/p>\n<p style=\"text-align: justify;\"><strong>The Win-Win Situation for All<\/strong><\/p>\n<p style=\"text-align: justify;\">Gilead Sciences, Inc. (NASDAQ:GILD) will be able to attract lesser criticism regarding the higher price of Solvadi, which kept it out of patient\u2019s reach in low-income countries. Gilead Sciences will be able to do so by allowing generic drug companies to sell less expensive versions of those drugs and keeping the price intact in the U.S. Meanwhile, companies in India are in a position to charge less because of lower manufacturing costs.<\/p>\n<p style=\"text-align: justify;\">The Head of Medical Affairs and Corporate Affairs of Gilead Sciences, <em>Gregg Alton<\/em> said that\u00a0Gilead Sciences, Inc. (NASDAQ:GILD) believes that capability and competition of partners will be able to cut down on price of such drugs. This will be done in not just Indian system, but also the health-care systems across the length and breadth of globe.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 In order to sell hepatitis C pill- Sovaldi, in developing countries like South Africa, Vietnam and Honduras, Gilead Sciences, Inc. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":17566,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264,263],"tags":[9197,1978,9149,5868,1522,5869,9196,9195,9198],"stock_ticker":[],"class_list":["post-31259","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-technology","tag-cipla-ltd-adr-otcmktscplfy","tag-gilead-sciences-inc-nasdaqgild","tag-gregg-alton","tag-mylan-inc-nasdaqmyl","tag-nasdaqgild","tag-nasdaqmyl","tag-otcmktsrbxly","tag-ranbaxy-laboratories-limited-adr-otcmktsrbxly","tag-tcmktscplfy","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 In order to sell hepatitis C pill- Sovaldi, in developing countries like South Africa, Vietnam and Honduras, Gilead Sciences, Inc. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-16T15:44:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations\",\"datePublished\":\"2014-09-16T15:44:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259\"},\"wordCount\":361,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\",\"keywords\":[\"Cipla Ltd (ADR) (OTCMKTS:CPLFY)\",\"Gilead Sciences Inc (NASDAQ:GILD)\",\"Gregg Alton\",\"Mylan Inc (NASDAQ:MYL)\",\"NASDAQ:GILD\",\"NASDAQ:MYL\",\"OTCMKTS:RBXLY\",\"Ranbaxy Laboratories Limited (ADR) (OTCMKTS:RBXLY)\",\"TCMKTS:CPLFY\"],\"articleSection\":[\"Health\",\"Technology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259\",\"name\":\"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\",\"datePublished\":\"2014-09-16T15:44:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\",\"width\":1024,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations - Wall Street PR","og_description":"Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 In order to sell hepatitis C pill- Sovaldi, in developing countries like South Africa, Vietnam and Honduras, Gilead Sciences, Inc. [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-16T15:44:37+00:00","og_image":[{"width":1024,"height":380,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations","datePublished":"2014-09-16T15:44:37+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259"},"wordCount":361,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","keywords":["Cipla Ltd (ADR) (OTCMKTS:CPLFY)","Gilead Sciences Inc (NASDAQ:GILD)","Gregg Alton","Mylan Inc (NASDAQ:MYL)","NASDAQ:GILD","NASDAQ:MYL","OTCMKTS:RBXLY","Ranbaxy Laboratories Limited (ADR) (OTCMKTS:RBXLY)","TCMKTS:CPLFY"],"articleSection":["Health","Technology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259","url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259","name":"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","datePublished":"2014-09-16T15:44:37+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","width":1024,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-collaborates-with-indian-pharmas-for-cheaper-hepatitis-c-drug-in-developing-nations-31259#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=31259"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31259\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/17566"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=31259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=31259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=31259"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=31259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}